Eli Lilly Stock - Weekly review and sector comparison after muted share pullback
19.06.2026 - 18:38:24 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:36 CET. Details in the imprint.
Eli Lilly & Co. (US5324571083) remains one of the most highly valued pharma names worldwide, even after a recent soft patch in trading this week. The move comes as investors reassess large-cap drugmakers and obesity leaders across the sector.
All news and analysis on Eli Lilly stock
Key figures, ad-hoc updates and background reports on Eli Lilly stock are bundled in our dedicated topic area for this S&P 500 heavyweight.
How Eli Lilly shares performed this week
According to market data, Eli Lilly shares recently closed around $1,098 on Nasdaq, down roughly 1.2% on the latest trading day. That compares with a broadly firmer US equity market in the same session, as reported by several data providers.
Short-term performance remains robust despite the pullback. Over roughly one month, Eli Lilly stock is still up close to 8%, underlining how strongly the market has re-rated the group this year on obesity and diabetes growth prospects.
Position in the pharma and obesity sector
With a market capitalization near $1.0 trillion, Eli Lilly currently stands among the most valuable healthcare companies globally and one of the largest members of the Standard & Poor's 500 index. This valuation clearly prices in strong expectations for its obesity and diabetes franchises.
Peer comparisons show that the broader big-pharma space trades on materially lower earnings multiples, while Lilly’s price-to-earnings ratio is close to 40 times trailing earnings, according to recent quote data. That premium highlights investor confidence but also leaves little room for operational missteps.
How Eli Lilly makes its money
Eli Lilly generates revenue primarily from prescription medicines in diabetes, obesity, immunology, oncology and neuroscience. Flagship products include the GLP-1 obesity drug Zepbound and the diabetes therapy Mounjaro, alongside long-standing brands in insulin and cancer treatments, as detailed on the company’s website.
Where the stock trades today
The shares of Eli Lilly & Co. (US5324571083) trade on the Nasdaq at $1,098.78 as of 06/18/2026, 16:00 ET.
Key facts on Eli Lilly stock
- Company: Eli Lilly and Company
- ISIN: US5324571083
- WKN: 858560
- Ticker: LLY
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 1,098.78 USD
- Market cap: 1,030,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
